DE60004196D1 - Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz - Google Patents

Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz

Info

Publication number
DE60004196D1
DE60004196D1 DE60004196T DE60004196T DE60004196D1 DE 60004196 D1 DE60004196 D1 DE 60004196D1 DE 60004196 T DE60004196 T DE 60004196T DE 60004196 T DE60004196 T DE 60004196T DE 60004196 D1 DE60004196 D1 DE 60004196D1
Authority
DE
Germany
Prior art keywords
maleacyl
pyrdyl
dion
thiazolidin
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60004196T
Other languages
English (en)
Other versions
DE60004196T2 (de
Inventor
David Blackler
Marie Browne
G Coakley
Gordon Giles
Gillian Morrissey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Cork Ltd
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60004196(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909473.2A external-priority patent/GB9909473D0/en
Priority claimed from GBGB9912196.4A external-priority patent/GB9912196D0/en
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Cork Ltd filed Critical SmithKline Beecham Ltd
Publication of DE60004196D1 publication Critical patent/DE60004196D1/de
Application granted granted Critical
Publication of DE60004196T2 publication Critical patent/DE60004196T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60004196T 1999-04-23 2000-04-19 Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz Expired - Fee Related DE60004196T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9909473.2A GB9909473D0 (en) 1999-04-23 1999-04-23 Novel compounds
GB9909473 1999-04-23
GB9912196 1999-05-25
GBGB9912196.4A GB9912196D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical
PCT/GB2000/001520 WO2000064896A1 (en) 1999-04-23 2000-04-19 Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt

Publications (2)

Publication Number Publication Date
DE60004196D1 true DE60004196D1 (de) 2003-09-04
DE60004196T2 DE60004196T2 (de) 2004-04-15

Family

ID=26315461

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60004196T Expired - Fee Related DE60004196T2 (de) 1999-04-23 2000-04-19 Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz

Country Status (40)

Country Link
US (2) US6806280B1 (de)
EP (2) EP1173435B1 (de)
JP (1) JP2002543077A (de)
KR (1) KR100744360B1 (de)
CN (1) CN1167702C (de)
AP (1) AP1598A (de)
AR (2) AR023561A1 (de)
AT (1) ATE246191T1 (de)
AU (1) AU765005B2 (de)
BG (1) BG65485B1 (de)
BR (1) BR0009932A (de)
CA (1) CA2370280A1 (de)
CO (1) CO5170421A1 (de)
CZ (1) CZ20013800A3 (de)
DE (1) DE60004196T2 (de)
DK (1) DK1173435T3 (de)
DZ (1) DZ3156A1 (de)
EA (1) EA004541B1 (de)
ES (1) ES2203453T3 (de)
HK (1) HK1045153B (de)
HR (1) HRP20010772B1 (de)
HU (1) HUP0200931A3 (de)
IL (1) IL146111A0 (de)
MA (1) MA25356A1 (de)
MX (1) MXPA01010821A (de)
MY (1) MY131973A (de)
NO (1) NO320574B1 (de)
NZ (1) NZ515168A (de)
OA (1) OA11872A (de)
PE (1) PE20010044A1 (de)
PL (1) PL351684A1 (de)
PT (1) PT1173435E (de)
SK (1) SK286427B6 (de)
TR (1) TR200103062T2 (de)
TW (1) TWI283677B (de)
UA (1) UA67844C2 (de)
UY (1) UY26121A1 (de)
WO (1) WO2000064896A1 (de)
YU (1) YU75301A (de)
ZA (1) ZA200108719B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
HUP0200929A3 (en) 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
JP2004509961A (ja) * 2000-09-26 2004-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 5−[4−[2−[n−メチル−n−(2−ピリジル)アミノ]エトキシ]ベンジル]チアゾリジン−2,4−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2002255017B2 (en) * 2002-04-19 2008-11-13 Faes Farma, S.A. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic acid
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (de) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphe Formen von Rosiglitazon Maleat
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005073227A2 (en) * 2004-01-28 2005-08-11 Usv Limited A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (de) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Verfahren zur Herstellung fester Dosierungsformen von Rosiglitazonmaleat
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (de) 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
US6462337B1 (en) * 2000-04-20 2002-10-08 Agilent Technologies, Inc. Mass spectrometer electrospray ionization
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US6632947B2 (en) * 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US7091359B2 (en) * 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US6613785B2 (en) * 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
CO5170419A1 (es) 1999-04-23 2002-06-27 Smithkline Beecham Plc Nuevo compuesto antidiabetico con base en sales del acido maleico
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
HUP0200929A3 (en) * 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
JP2004509961A (ja) 2000-09-26 2004-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 5−[4−[2−[n−メチル−n−(2−ピリジル)アミノ]エトキシ]ベンジル]チアゾリジン−2,4−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法

Also Published As

Publication number Publication date
AU765005B2 (en) 2003-09-04
CZ20013800A3 (cs) 2002-04-17
ES2203453T3 (es) 2004-04-16
AR023561A1 (es) 2002-09-04
SK286427B6 (sk) 2008-09-05
EP1173435A1 (de) 2002-01-23
MXPA01010821A (es) 2003-09-04
CN1167702C (zh) 2004-09-22
HRP20010772A2 (en) 2002-10-31
NO320574B1 (no) 2005-12-27
CN1356999A (zh) 2002-07-03
DZ3156A1 (fr) 2000-11-02
AU4130800A (en) 2000-11-10
HRP20010772B1 (en) 2007-05-31
EP1173435B1 (de) 2003-07-30
SK14922001A3 (sk) 2002-02-05
BR0009932A (pt) 2002-04-09
AR023565A1 (es) 2002-09-04
HUP0200931A2 (en) 2002-08-28
MA25356A1 (fr) 2001-12-31
BG106121A (en) 2002-05-31
WO2000064896A9 (en) 2001-10-25
EA004541B1 (ru) 2004-06-24
US20050080114A1 (en) 2005-04-14
US6806280B1 (en) 2004-10-19
EA200101121A1 (ru) 2002-04-25
ATE246191T1 (de) 2003-08-15
EP1304330A2 (de) 2003-04-23
TR200103062T2 (tr) 2002-05-21
UA67844C2 (uk) 2004-07-15
EP1304330A3 (de) 2003-11-19
NZ515168A (en) 2004-02-27
KR100744360B1 (ko) 2007-07-30
AP2001002330A0 (en) 2000-12-31
OA11872A (en) 2006-03-27
NO20015147L (no) 2001-12-17
IL146111A0 (en) 2002-07-25
AP1598A (en) 2006-04-26
PT1173435E (pt) 2003-12-31
ZA200108719B (en) 2002-06-21
YU75301A (sh) 2004-07-15
HUP0200931A3 (en) 2004-03-29
WO2000064896A1 (en) 2000-11-02
MY131973A (en) 2007-09-28
PL351684A1 (en) 2003-06-02
HK1045153A1 (en) 2002-11-15
BG65485B1 (bg) 2008-09-30
DK1173435T3 (da) 2003-11-24
CA2370280A1 (en) 2000-11-02
DE60004196T2 (de) 2004-04-15
HK1045153B (zh) 2004-07-09
PE20010044A1 (es) 2001-03-10
KR20010110797A (ko) 2001-12-13
UY26121A1 (es) 2000-12-29
TWI283677B (en) 2007-07-11
NO20015147D0 (no) 2001-10-22
JP2002543077A (ja) 2002-12-17
CO5170421A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
DE60004196D1 (de) Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
DE60112729D1 (de) Hcl-salze von 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dion
NO20003069L (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
IL136381A0 (en) Hydrate of 5-[4-[2-(n- methyl-n-(2-(pyridil)amino) ethoxy]benzyl] thiazolidine-2,4- dione maleic acid salt
NO995938D0 (no) Blanding omfattende 5-[4-[2-(N-metyl-N-2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
NO20031020D0 (no) Hydrokloridsalt av 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion
IL188116A0 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2,4-dione
NO20025882L (no) 5-(4-(2-(N-metyl-N-(2-pyridyl)amino)etoksy)benzyl)-tiazolidin- 2,4-dion hydriodid som farmasöytisk middel
SI1173435T1 (en) Polymorph of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleic acid salt
SI1265893T1 (sl) Hidrokloridne soli 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil)tiazolidin-2,4-diona

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee